303 results about "Need treatment" patented technology

The present invention provides a method and apparatus for detecting and treating sleep respiratory events that includes a plurality of sensors gathering physiological data related to sleep respiratory events. A processor extracts an average cycle length and a frequency of at least one of Cheyne-Stokes respiration and periodic breathing based upon the physiological data, and determines whether therapy is required based on the average cycle length and the frequency.

Disclosed are techniques for operation of neurostimulation or drug delivery devices to stop treatment therapy during times when the patient does not need to be treated. Advantageously, the present invention reduces battery usage and / or drug dosage during periods when treatment therapy need not be provided. Further, the present invention slows or reduces the tolerance the patient may develop from the electrical stimulation or treatment therapy. In one embodiment, the present invention includes a timer or a real time clock for shutting off the device during periods when the patient is sleeping in accordance with a preset schedule. The present invention preferably turns off after the patient has fallen asleep and right before the patient has awakened. Alternatively, the invention may include a sensor for sensing conditions indicative of whether the patient is awake or asleep. This sensed information may also be used to determine whether the treatment therapy should be delivered or stopped.

The present invention provides a method and apparatus for detecting and treating sleep respiratory events that includes a plurality of sensors gathering physiological data related to sleep respiratory events. A processor extracts an average cycle length and a frequency of at least one of Cheyne-Stokes respiration and periodic breathing based upon the physiological data, and determines whether therapy is required based on the average cycle length and the frequency.

The present invention provides a treatment apparatus. The apparatus contains a reservoir or generator for a treatment solution, a mechanism for delivering the treatment solution to a wound site, and a mechanism for applying the solution to a wound, tissue, bone or surgical cavity for treatment. The apparatus may apply the solution (e.g., a solution containing hypohalous acid) with, for example, an occlusive wound dressing, pulsative lavage device, hydrotherapy, hydrosurgical device, and / or ultrasound. A waste container may be operably connected to the apparatus for collecting waste from the wound by run-off, or by applying negative pressure (e.g. a vacuum). Because the apparatus of the invention can optionally be portable or mobile, the invention is suitable for use in hospitals and nursing homes, as well as for home wound care. The invention also provides a method for treating a wound (or other area needing treatment), and / or for reducing wound bioburden, by supplying a hypochlorous acid solution to the site, such as a wound colonized or infected with drug resistant bacteria, before, during, or after negative pressure wound therapy.

In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g., one or more single nucleotide polymorphisms, that at least partly differentiate between a subset of a plurality of individuals who experience a response when administered an insulin sensitizer, and a subset of said plurality of individuals who do not experience a response when administered the insulin sensitizer. The invention also provides nucleic acids, polypeptides, antibodies, kits, and business methods associated with these screening and association methods.

Athletic and sports wear, and medical or therapeutic garments (G1-G8), all made from a “smart” fabric. The fabric is woven from, or incorporates, one or more components that allows the fabric to change size or shape, project heat or cooling to a part of the wearer's body, to monitor body vital signs such as temperature and pulse rate, etc. The fabric can be used in a garment covering only part of a patient's body, or substantially all of the body. Besides targeting specific areas of a body for treatment, garments made from the fabric facilitate zonal treatments; that is, areas of the body that require therapy but in which certain portions of the area require different levels or intensity of treatment than others. A variety of materials and their various capabilities are disclosed.

The present invention relates to methods of preventing or inhibiting the growth of Helicobacter through the use of a composition that comprises a glucosinolate, an isothiocyanate or a derivative or metabolite thereof. The present invention also relates to methods of preventing or treating persistent chronic gastritis, ulcers and / or stomach cancer in subjects at risk for, or in need of treatment thereof.

Apparatus and method for harvesting energy from the environment and / or other external sources and converting it to useful electrical energy. The harvester does not contain a permanent magnet or other local field source but instead relies on the earth's magnetic field of another source of a magnetic field that is external to the sensing device. One advantage of these new harvesters is that they can be made smaller and lighter than energy harvesters that contain a magnet and / or an inertial mass. A small implantable stimulator(s) includes at least one passive magnetostrictive / electro-active (PME) magnetic-field sensor for delivering electrical stimulation to surrounding tissue. The PME is charged utilizing a changing magnetic field from an external alternating magnetic field source at a frequency particular to the PME. The small stimulator provides means of stimulating a nerve, tissue or internal organ with direct electrical current, such as relatively low-level direct current for temporary or as needed therapy. The field source may be a hand-held device or a small antenna affixed to the wearer's skin, clothing or accessories. The stimulator may be configured to be small enough to be implanted through a surgical needle. Open- and closed-loop systems are disclosed with measurement of current flow and therapy through PME sensor function.

Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and / or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.

A system and method to predict and assess immunogenicity, especially prior to on-set of immunogenic conditions. Also disclosed are methods to identify relevant peptides associated with the formation of antibodies in patients treated with a given protein therapeutic. In various aspects, the present application is directed to methods of determining the immunological compatibility of a subject with a therapeutic agent such as a proteinaceous therapeutic agent, methods of determining vaccine efficacy by determining the immunological compatibility of a subject with a therapeutic agent, and selecting a therapeutic agent for a subject in need of treatment. Methods of designing a therapeutic agent with reduced immunogenicity for a subject and methods for designing vaccines with enhanced immunogenicity for a subject are also contemplated.

A method for treating an allergic reaction other than asthma in a mammal need thereof comprising administering to said mammal a tetracycline compound in an amount that is effective to treat said allergic reaction.

Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK / STAT signaling, are provided, comprising determining the level of the JAK / STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK / STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.

In a method and system for monitoring the course of therapy administered to a patient, at least one information value that requires a therapeutic and / or diagnostic measure and that is a direct or indirect measure of the course of the therapy is registered continuously or in time intervals, and at least one comparison value, to be compared to the information value or to a calculated value determined based on the information value, is allocated to the information value. An alarm signal is emitted given an impermissible deviation of the information value or of the calculated value from the comparison value and is detected in the course of the comparison. The comparison value is varied dependent on the course of the therapy and is adapted to the course of the therapy, the adaptation of ensuing automatically or by means of an authorized person or entity.

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and / or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

An apparatus for modifying a keratinous surface that has a rotatable applicator that is in fluid communication with a first modification composition. The apparatus also has a sensor and a CPU. The sensor is positioned forward of the applicator head such that as the head rolls across the keratinous surface the sensor reads the portion of the keratinous surface in front of the rolling head. The sensor readings are transmitted to the CPU, the CPU analyzes the sensor readings of the keratinous surface, and the CPU sends a signal to the applicator head to treat or not to treat the analyzed surface. When the CPU sends a signal to the applicator to treat the surface, a small portion of the first modification composition is applied to the head such that when the head rolls over the keratinous surface the first modification composition contacts the area of the keratinous surface that needs treatment.

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and / or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein [0001]R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; [0002]or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; [0003]X and Y are independently selected from O, S, NH, and (CR6R7)n; [0004]R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; [0005]Z is N or CR4; [0006]R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; [0007]R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; [0008]R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; [0009]at least one of R1, R2 and R4 is other than hydrogen; and [0010]at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula I.

A human shoulder stretcher and method of use for gradual, progressive posterior capsular stretching to rehabilitate the shoulder, in particular to address tightness of the posterior capsule of the glenohumeral joint through use of a lever arm and ratcheting mechanism that permits a patient to stretch his or her shoulder without the need for a therapist present.

The present invention relates to method for the treatment of contact lens related dry eye comprising contacting the surface of the eye of a patient in need of treatment for contact lens related dry eye with a contact lens having specified properties.

The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.

Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and / or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:whereinR1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5;or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group;X and Y are independently selected from O, S, NH, and (CR6R7)n;R3 is hydrogen, alkyl or M+;M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof;Z is N or CR4;R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5;R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl;R6 and R7 are independently selected from hydrogen and alkyl;n is an integer from 1 to 6;at least one of R1, R2 and R4 is other than hydrogen; andat least one of X and Y is (CR6R7)n.D-serine or cycloserine may be coadministered along with the compound of formula I.

Provided are means for the direct and continuous connection of a catheter to the lumen of any tubular anatomical structure, or ductus, without medically significant leakage. A port implanted at the body surface with piping to a periductal collar allows drug or radionuclide delivery that bypasses the upstream lumen. The port allows injection, infusion, or attachment of an automatic ambulatory pump. A superparamagnetic nanoparticle carrier-bound drug, for example, can be introduced into the lumen to pass downstream until the carrier particles, with or without the drug still bound, are drawn into the lumen wall by a magnetized jacket surrounding the ductus. Such constitutes a method of drug targeting whereby a segment of a vessel or the territory supplied by a branch of that segment can be circumscribed for exposure to the drug. A jacket with side-entry connector positioned in surrounding relation to a lesion requiring treatment can itself be magnetized.

Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and / or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.

A system and method for conservation of battery power in a portable medical device is provided. In one example, a processor arrangement includes a dual core processor having an ARM core and a DSP core. The portable medical device includes a monitor having the dual core processor, in communication with a belt node processor. The DSP core receives physiological data from the physiological sensor and sends the physiological data to the ARM core. The ARM core analyzes the physiological data to determine if a treatment sequence is necessary. The DSP core receives physiological data from the at least one physiological sensor and sends the physiological data to the ARM core, and also analyzes the physiological data to determine proper timing of the treatment sequence by the at least one therapy delivery device to synchronize at least one pulse of the treatment sequence with the physiological data.

A portable phototherapy apparatus for treating a skin disorder in a patient. The apparatus includes an illumination source, an image capture device, a projecting system and a controller. The illumination source is configured to irradiate the patient's skin. The image capture device for capturing an image of lesion areas of the patient's skin needing treatment. The projecting system includes a therapeutic light source for generating UV radiation. The controller configured to cause the projecting system to form a shaped treatment image comprising the UV radiation on the patient's skin based on the image of the lesion areas captured by the image capture device such that the therapeutic light source delivers a dose of the UV radiation only to the lesion areas of the skin.

Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

The present invention relates to a method and system for presenting targeted advertising to a patient in need of a therapeutic treatment plan. By providing an electronic device such as a PDA or the like a series of questions can be asked of the patient to come to a diagnosis or condition in need of treatment. Then appropriate targeted advertising can be given to the patient by the device in order to encourage choosing a particular product for treatment or the like.